Valuation: Ocular Therapeutix, Inc.

Market Cap 1.79B 1.56B 1.45B 1.33B 2.51B 171B 2.55B 17.06B 6.7B 85.02B 6.72B 6.57B 285B P/E 2026 *
-5.1x
P/E 2027 * -5.8x
Enterprise Value 1.43B 1.24B 1.15B 1.06B 2B 136B 2.03B 13.6B 5.34B 67.77B 5.36B 5.24B 227B EV / Sales 2026 *
27.5x
EV / Sales 2027 * 14.7x
Free-Float
99.06%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ocular Therapeutix, Inc.

1 day-3.54%
1 week-3.94%
1 month-15.25%
3 months-13.36%
6 months-10.71%
Current year-32.70%
1 week 8.15
Extreme 8.15
8.66
1 month 8.15
Extreme 8.15
10.94
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 15/04/2024
Director of Finance/CFO 50 20/01/2026
Chief Tech/Sci/R&D Officer 49 20/05/2024
Director TitleAgeSince
Chairman 57 01/07/2019
Director/Board Member 78 05/11/2012
Director/Board Member 66 20/03/2019
Date Insider Type Main position Quantity % Market Cap.
23/02/26 Sell

Executive/Senior Manager

1,759 0.0008%
23/02/26 Sell

Executive/Senior Manager

2,810 0.0013%
23/02/26 Sell

Chief Technology Officer

3,057 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
+3.12%-3.94%-31.46%+90.00% 1.79B
-2.08%-3.95%+50.70%+152.78% 1,024B
-1.37%-2.68%+53.20%+50.87% 618B
-1.59%-3.25%+28.54%+67.99% 443B
+0.74%-0.81%+40.08%+33.81% 349B
-0.79%-1.43%+33.94%+42.24% 297B
-7.92%-6.71%+7.97%+10.31% 264B
-0.64%-5.93%-1.87%-42.77% 209B
+0.01%+2.43%+29.74%+67.16% 208B
+0.06%+0.70%+15.05%+72.05% 162B
Average -0.42%-1.60%+22.59%+54.44% 357.55B
Weighted average by Cap. +0.34%-2.17%+36.86%+73.28%

Financials

2026 *2027 *
Net sales 51.91M 45.12M 42M 38.56M 72.82M 4.96B 73.95M 495M 194M 2.47B 195M 191M 8.27B 120M 105M 97.38M 89.4M 169M 11.49B 171M 1.15B 450M 5.72B 452M 442M 19.18B
Net income -362M -314M -293M -269M -507M -34.53B -515M -3.45B -1.35B -17.19B -1.36B -1.33B -57.65B -331M -287M -267M -246M -464M -31.56B -471M -3.15B -1.24B -15.71B -1.24B -1.21B -52.68B
Net Debt -363M -316M -294M -270M -509M -34.65B -517M -3.46B -1.36B -17.25B -1.36B -1.33B -57.85B -18M -15.65M -14.56M -13.37M -25.25M -1.72B -25.64M -172M -67.38M -855M -67.6M -66.12M -2.87B
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
03/08/26 $8.355 +2.26% 232,652
31/07/26 $8.170 -3.54% 2,151,848
30/07/26 $8.470 +1.32% 2,686,427
29/07/26 $8.360 -1.07% 1,785,320
28/07/26 $8.450 -2.20% 2,373,435
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
8.170USD
Average target price
27.09USD
Spread / Average Target
+231.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock